Holen Sie sich die Stockscreener-App
2.16
68.75%
0.88
Handel nachbörslich:
2.03
-0.13
-6.02%
Io Biotech Inc Aktie (IOBT) Neueste Nachrichten
RSI Reset May Fuel Rebound in IO Biotech Inc.2025 Performance Recap & Accurate Intraday Trading Signals - beatles.ru
IO Biotech Surges 21.1% on Clinical Trial Optimism and Extended Cash Runway - AInvest
IO Biotech’s Experimental Vaccine Shakes Market - StocksToTrade
Is IO Biotech’s Stock Soaring Too High? - timothysykes.com
Why Did IO Biotech Stock Soar 10.94%? - AInvest
Io Biotech shares rise 16.41% premarket after reporting clinical improvement in pivotal Phase 3 Trial of Cylembio® plus KEYTRUDA®. - AInvest
Trendlines Converge — Decision Point for IO Biotech Inc.Jobs Report & Free Weekly Chart Analysis and Trade Guides - beatles.ru
IO Biotech Posts Wider Loss in Q2, Misses Primary Endpoint in Phase 3 Trial for Cylembio in Advanced Melanoma - AInvest
Io Biotech Posts Wider Loss in Q2 - Nasdaq
IO Biotech's Earnings Miss and Path to Recovery: Assessing Long-Term Value Amid Short-Term Setbacks - AInvest
IO Biotech Inc reports results for the quarter ended June 30Earnings Summary - TradingView
IO Biotech's Melanoma Vaccine Trial Falls Short of Statistical Goals Despite Clinical Benefits - Stock Titan
Biotech Stocks Rally as Oncology Market Targets $866B by 2034 - Cantech Letter
IO Biotech says cancer vaccine with Merck’s Keytruda outperformed in late-stage study - MSN
IO Biotech shares fall 2.29% premarket after Phase 3 trial results narrowly missed statistical significance. - AInvest
Morgan Stanley Maintains IO Biotech(IOBT.US) With Buy Rating, Maintains Target Price $4 - 富途牛牛
IO Biotech sees potential despite cancer vaccine study failure. - AInvest
IO Biotech: A Buying Opportunity Following Phase 3 Readout In Melanoma - Seeking Alpha
IO Biotech - The Pharma Letter
IO Biotech Surges 32.9% on Mixed Trial Data: Can Clinical Promise Outpace Regulatory Doubts? - AInvest
IO Biotech's cancer vaccine shows improvement, but narrowly misses study goal - Reuters
IO Biotech Inc expected to post a loss of 36 cents a shareEarnings Preview - TradingView
Does IO Biotech Inc. meet Warren Buffett’s criteriaFree Profit Target Calculator - thegnnews.com
IO Biotech, Inc.'s (NASDAQ:IOBT) Market Cap Dropped US$72m Last Week; Private Equity Firms Bore the Brunt - 富途牛牛
IO Biotech's Promising Phase 3 Results and FDA Engagement Bolster Buy Rating - AInvest
IO Bio plans cancer vaccine filing despite trial miss - pharmaphorum
IO Biotech's Cylembio Trial: Navigating Near-Miss Outcomes and FDA Pathways in Oncology Innovation - AInvest
IO Biotech's Near-Miss in Phase 3 Trial: A Case Study in Biotech Resilience and Strategic Value - AInvest
IO Biotech's Cylembio and KEYTRUDA Combo: A Near-Miss in Pivotal Trial—Is This a Buying Opportunity or a Cautionary Tale? - AInvest
IO Biotech Plans Cylembio Filing Despite ‘Narrowly Missed’ Phase III Endpoint - insights.citeline.com
IO Biotech stock price target lowered to $4 at Morgan Stanley By Investing.com - Investing.com South Africa
IO Biotech stock price target lowered to $4 at Morgan Stanley - Investing.com Canada
IO Biotech's Near-Miss in Cylembio Trial: A Lesson in Incremental Progress and Long-Term Value - AInvest
Skin tight: IO Biotech melanoma phase III misses ‘by a hair’ - BioWorld MedTech
IO Biotech (IOBT.O) Suffers Intraday Freefall: What’s Behind the 33.4% Drop? - AInvest
IO Biotech to pursue cancer vaccine approval despite Phase III miss - Yahoo Finance
IO Biotech Reports Positive Results for Cancer Vaccine with Merck's Keytruda in Late-Stage Trial - AInvest
IO Biotech's cancer vaccine shows improvement in late-stage study goal - MSN
Promising Phase 3 Results and Strategic FDA Engagement Bolster Buy Rating for IO Biotech - TipRanks
IO Biotech sees path forward for skin cancer vaccine despite study setback - BioPharma Dive
IO Biotech Plummets 23.7%: What’s Behind the Sharp Drop? - AInvest
IO Biotech Plummets 39% on Near-Miss in Key Trial, Hints at FDA Gambit - AInvest
IO Biotech to seek FDA filing even though cancer vaccine narrowly fails pivotal skin cancer study - Endpoints News
IO Biotech's cancer vaccine Cylembio falls short in Phase III melanoma trial - FirstWord Pharma
IO Biotech Shares Climb Following Encouraging Cancer Vaccine Trial Results - MSN
Mixed results for IO Biotech's cancer vaccine Cylembio - The Pharma Letter
IO Biotech Stock Slumps After Trial Of Cancer Therapy Plus Keytruda Misses Study Goal: Retail Sees Shares Rise 10x - Stocktwits
IO Biotech drops after cancer vaccine narrowly misses main goal of late-stage study - TradingView
IO Biotech's Phase 3 Trial Fails To Deliver (NASDAQ:IOBT) - Seeking Alpha
IO Biotech's Skin Cancer Vaccine Combo Falls Short of Expectations, Seeks FDA Approval - AInvest
IO Biotech’s cancer vaccine shows improvement, but narrowly misses study goal - The Mighty 790 KFGO
Why Is IO Biotech Stock Falling Monday?IO Biotech (NASDAQ:IOBT) - Benzinga
IO Biotech’s cancer jab falls short in Phase 3, but Danish firm still eyes FDA approval - European Biotechnology Magazine
Transcript : IO Biotech, Inc.Special Call - MarketScreener
Cancer vaccine’s ‘narrow’ phase 3 fail won’t stop IO heading to FDA - Fierce Biotech
Danish cancer vaccine just misses the mark in phase 3 trial - medwatch.com
Pharma Boom: What’s Up With IO Biotech? - timothysykes.com
IO Biotech's Cylembio: A Game-Changing Cancer Vaccine with Strong Clinical Signal and Regulatory Pathway Potential - AInvest
IO Biotech stock rises as cancer vaccine shows promising results By Investing.com - Investing.com South Africa
IO Biotech stock rises as cancer vaccine shows promising results - Investing.com
IO Biotech announces clinical improvement in progression free survival demonstrated in pivotal phase 3 trial of cylembio plus Keytruda (pembrolizumab) for the treatment of first-line advanced melanoma, but statistical significance narrowly missed - MarketScreener
IO Biotech Shares Jump in Premarket on Positive Melanoma Treatment Trial Data - MarketScreener
Navigating the Crossroads: IO Biotech's Cylembio and the Regulatory Hurdles of a Novel Cancer Vaccine - AInvest
IO Biotech Reveals Phase 3 Trial Results for Cylembio - TipRanks
IO Biotech stock jumps on data for cancer shot (IOBT:NASDAQ) - Seeking Alpha
IO Biotech's cancer vaccines shows improvement in late-stage study goal - MarketScreener
0.41%
0.88%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):